

, Su Jong Yu1,3*
, Sung Hak Lee1,4
, Min Woo Lee1,5
, Han Ah Lee1,6
, Yuri Cho1,7
, Jeong-Ju Yoo1,8
, Ha Il Kim1,9
, Jae Geun Lee1,10
, Hye Won Lee1,11
, Jihyun An1,9
, Sun Young Yim1,12
, Pil Soo Sung1,2
, Jonggi Choi1,13
, Jae Hyun Yoon1,14
, Eun Ju Cho1,3
, Jinhong Jung1,15
, Dongho Hyun1,16
, Ijin Joo1,17
, Yu Rim Lee1,18
, YoungRok Choi1,19
, Bo Hyun Kim1,7
, Sung Hyun Kim1,20
, Soon Sun Kim1,21
, Jeong-Han Kim1,22
, Haeryoung Kim1,23
, Pyoung-Jae Park1,24
, Hyun Phil Shin1,25
, Ki Tae Yoon1,26,27
, Sang Min Yoon1,15
, Minjong Lee1,28,29
, Jai Young Cho1,30
, Jin-Young Choi1,31
, Do Young Kim1,11
, June Sung Lee1,32
, Mi-Sook Kim1,33
, Kyung Sik Kim1,20
on behalf of the 26th Scientific Committee of the Korean Liver Cancer Association 1The Korean Liver Cancer Association, Seoul, Korea
2Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
4Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
5Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
6Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea
7Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea
8Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
9Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
10Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
11Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
12Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
13Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
14Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
15Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
16Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
17Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
18Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
19Department of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
20Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine; Seoul, Korea
21Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea
22Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea
23Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
24Division of Transplantation and Vascular Surgery, Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
25Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea
26Department of Internal Medicine, Pusan National University College of Medicine, Yangsan, Korea
27Liver Center, Pusan National University Yangsan Hospital, Yangsan, Korea
28Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
29Department of Internal Medicine, Ewha Womans University Medical Center, Seoul, Korea
30Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
31Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
32Department of Internal Medicine, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
33Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, Korea
Copyright © 2026 by The Korean Liver Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interests
Haeryoung Kim, Jeong-Ju Yoo, Hye Won Lee, Pil Soo Sung, and Sun Young Yim were Editorial Board members of Journal of Liver Cancer at the time of submission and revision, and were not involved in the review process of this article.
Su Jong Yu, Han Ah Lee, Yuri Cho, Jae-Geun Lee, Jihyun An, Jinhong Jung, Dong Ho Hyun, Hyun Phil Shin, Sang Min Yoon, and Minjong Lee became Editorial Board members of Journal of Liver Cancer following the board transition on July 1, 2026, and were not involved in the peer review or decision-making process for this manuscript. Otherwise, the authors have no conflicts of interest to disclose.
Ethics Statement
This study was based solely on previously published literature and did not involve the recruitment of additional patient participants; therefore, IRB approval was not required. An expert survey was conducted on a voluntary basis after participants were informed of the study purpose, and completion of the survey was considered to imply consent; thus, the requirement for written informed consent was waived.
Funding Statement
This study was supported by the Internal Research Fund of the Korean Liver Cancer Association for 2019 (KLCA-19-01).
Author Contributions
Conceptualization: HLL, SJY, KSK
Data curation: HLL, SJY, JA, JJY, IJ, YRL, YRC, BHK, SHK, SSK, JHK, HK, PJP, HPS, KTY, SMY, ML
Formal analysis: HLL, SJY
Funding acquisition: SJY
Investigation: SHL, MWL, HAL, YC, HIK, JGL, HWL, JA, SYY, PSS, JC, JHY, EJC, JJ, DH, IJ, YRL, YRC, BHK, SHK, SSK, JHK, HK, PJP, HPS, KTY, SMY, ML, JYC, JYCh, DYK, JSL, MSK
Methodology: HLL, SJY
Project administration: SJY, KSK
Resources: SHL, MWL, YC, JHY, EJC, DH, YRC, BHK, SHK, SSK, JHK, HK, PJP, HPS, KTY, SMY, ML
Supervision: SJY, KSK
Validation: HLL, SJY
Visualization: MWL, HLL, SJY
Writing - original draft: HLL, SJY, SHL, MWL
Writing - review & editing: HLL, SJY, SHL, MWL, HAL, YC, JJY, HIK, JGL, HWL, JA, SYY, PSS, JC, JHY, EJC, JJ, DH, IJ, YRL, YRC, BHK, SHK, SSK, JHK, HK, PJP, HPS, KTY, SMY, ML, JYC, JYCh, DYK, JSL, MSK, KSK
| Guideline | Recommendations* |
|---|---|
| AASLD 2023 | AASLD recommends considering liver biopsy for lesions categorized as LR-4 and LR-5 on non-invasive imaging, both to confirm the diagnosis and to enable molecular profiling |
| EASL 2025 |
Routine molecular analysis is not recommended (Level of Evidence 3, strong recommendation); however, liver biopsy may be performed for research purposes when deemed essential for advancing precision medicine When performing liver biopsy, it is suggested to obtain non-tumoral tissue for facilitating diagnosis, assessing fibrosis and inflammation, and evaluating comorbid factors, such as steatosis (Level of Evidence 3, weak recommendation) |
| BSG 2024 | Tumor biopsy should be performed for HCC lesions when systemic therapy is being considered (evidence moderate; recommendation strong) |
| ESMO 2025 |
Tumor biopsy is recommended prior to the initiation of systemic therapy (Level III, Grade A) Next-generation sequencing should be considered for tumors with mixed histological features (Level IV, Grade A) To support biomarker development, tumor biopsy is recommended for all patients with HCC participating in clinical trials (Level IV, Grade A) |
HCC, hepatocellular carcinoma; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; BSG, British Society of Gastroenterology; ESMO, European Society for Medical Oncology.
* Excludes general pathological diagnostic criteria for HCC, such as in patients without risk factors for HCC or in cases lacking typical imaging features on noninvasive studies. Level of evidence and strength of recommendations are presented as stated in each guideline.
| Guideline | Hemostasis parameters and transfusion thresholds | Management of antiplatelet and anticoagulant agents |
|---|---|---|
| AASLD 2009 | No established cut-off for PT INR and platelet count predicting bleeding risk |
Discontinue antiplatelet agents several to ten days prior (Class I, Level C)* Discontinue anticoagulant agents, including warfarin at least 5 days prior (Class I, Level C) |
| EASL 2022 |
Hemostasis tests (PT INR, aPTT, platelet count, and fibrinogen) generally not predictive (Level of Evidence 3, strong recommendation) FFP correction of PT INR not recommended (Level of Evidence 2, strong recommendation) Platelet transfusion not recommended if >50×109/L or if bleeding can be locally controlled (Level of Evidence 3/4, strong recommendation) |
Manage antiplatelet and/or anticoagulant agents as in non-cirrhotic patients (Level of Evidence 4, strong recommendation) |
| BSG 2020 |
PT INR 1.5–2.0 not a contraindication but associated with increased bleeding risk in patients with hepatic fibrosis and portal hypertension (strength of recommendation moderate; evidence moderate) FFP not recommended if PT INR ≤2.0 (strength of recommendation strong; evidence moderate) Platelet transfusion may be considered if <50×109/L (strength of recommendation moderate; evidence weak) |
Stop clopidogrel, prasugrel, ticagrelor 7 days prior Aspirin, withhold 3–7 days prior Dual antiplatelet therapy, stop clopidogrel and continue aspirin |
| SIR 2019 |
Suggested cutoff PT INR ≤2.5 Platelet count ≥30×109/L Fibrinogen ≥100 mg/dL |
Aspirin, discontinue 3–5 days prior Clopidogrel, discontinue 5 days prior Additionally, the guideline provides recommendations for the management of other anticoagulant and antiplatelet agents |
AASLD, American Association for the Study of Liver Diseases; PT, prothrombin time; INR, international normalized ratio; EASL, European Association for the Study of the Liver; aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; BSG, British Society of Gastroenterology; SIR, Society of Interventional Radiology.
* Level of evidence and strength of recommendations are presented as stated in each guideline.
| Guideline | Recommendations |
|---|---|
| AASLD 2023 | AASLD recommends considering liver biopsy for lesions categorized as LR-4 and LR-5 on non-invasive imaging, both to confirm the diagnosis and to enable molecular profiling |
| EASL 2025 | Routine molecular analysis is not recommended (Level of Evidence 3, strong recommendation); however, liver biopsy may be performed for research purposes when deemed essential for advancing precision medicine When performing liver biopsy, it is suggested to obtain non-tumoral tissue for facilitating diagnosis, assessing fibrosis and inflammation, and evaluating comorbid factors, such as steatosis (Level of Evidence 3, weak recommendation) |
| BSG 2024 | Tumor biopsy should be performed for HCC lesions when systemic therapy is being considered (evidence moderate; recommendation strong) |
| ESMO 2025 | Tumor biopsy is recommended prior to the initiation of systemic therapy (Level III, Grade A) Next-generation sequencing should be considered for tumors with mixed histological features (Level IV, Grade A) To support biomarker development, tumor biopsy is recommended for all patients with HCC participating in clinical trials (Level IV, Grade A) |
| Guideline | Hemostasis parameters and transfusion thresholds | Management of antiplatelet and anticoagulant agents |
|---|---|---|
| AASLD 2009 | No established cut-off for PT INR and platelet count predicting bleeding risk | Discontinue antiplatelet agents several to ten days prior (Class I, Level C) Discontinue anticoagulant agents, including warfarin at least 5 days prior (Class I, Level C) |
| EASL 2022 | Hemostasis tests (PT INR, aPTT, platelet count, and fibrinogen) generally not predictive (Level of Evidence 3, strong recommendation) FFP correction of PT INR not recommended (Level of Evidence 2, strong recommendation) Platelet transfusion not recommended if >50×109/L or if bleeding can be locally controlled (Level of Evidence 3/4, strong recommendation) |
Manage antiplatelet and/or anticoagulant agents as in non-cirrhotic patients (Level of Evidence 4, strong recommendation) |
| BSG 2020 | PT INR 1.5–2.0 not a contraindication but associated with increased bleeding risk in patients with hepatic fibrosis and portal hypertension (strength of recommendation moderate; evidence moderate) FFP not recommended if PT INR ≤2.0 (strength of recommendation strong; evidence moderate) Platelet transfusion may be considered if <50×109/L (strength of recommendation moderate; evidence weak) |
Stop clopidogrel, prasugrel, ticagrelor 7 days prior Aspirin, withhold 3–7 days prior Dual antiplatelet therapy, stop clopidogrel and continue aspirin |
| SIR 2019 | Suggested cutoff PT INR ≤2.5 Platelet count ≥30×109/L Fibrinogen ≥100 mg/dL |
Aspirin, discontinue 3–5 days prior Clopidogrel, discontinue 5 days prior Additionally, the guideline provides recommendations for the management of other anticoagulant and antiplatelet agents |
HCC, hepatocellular carcinoma; AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; BSG, British Society of Gastroenterology; ESMO, European Society for Medical Oncology. Excludes general pathological diagnostic criteria for HCC, such as in patients without risk factors for HCC or in cases lacking typical imaging features on noninvasive studies. Level of evidence and strength of recommendations are presented as stated in each guideline.
AASLD, American Association for the Study of Liver Diseases; PT, prothrombin time; INR, international normalized ratio; EASL, European Association for the Study of the Liver; aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; BSG, British Society of Gastroenterology; SIR, Society of Interventional Radiology. Level of evidence and strength of recommendations are presented as stated in each guideline.